期刊
MEDCHEMCOMM
卷 7, 期 5, 页码 778-787出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/c5md00582e
关键词
-
资金
- Australian National Health and Medical Research Council [GNT1057742]
- Victorian State Government Operational Infrastructure Support (OIS) Grant
- Australian Cancer Research Foundation
- Leukemia & Lymphoma Society (Specialized Center of Research) [7001-13]
- Cancer Therapeutics CRC
- Dyson Bequest funding (Dunn Fellowship)
Mcl-1 (myeloid-cell-leukemia-sequence-1) is a pro-survival member of the Bcl-2 family of proteins. Mcl-1 has been shown to be critical to the survival of a variety of cancer cells and to mediate resistance to conventional and targeted chemotherapeutics. Whilst potent and selective small molecule inhibitors of Bcl-2 and Bcl-XL have been developed, the discovery of selective inhibitors of Mcl-1 has proven more problematic and only very recently have potent and selective inhibitors been described. In this review we outline key features of Mcl-1 biology, and chemical approaches and outcomes of inhibiting this important survival protein for the treatment of cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据